, universal childhood immunization programs in Canada changed from using a whole-cell pertussis to a 5-component acellular pertussis-containing vaccine. To assess effects on pertussis epidemiology of this nationwide change, we analyzed hospitalizations during 1991-2004 using the Canadian Immunization Monitoring Program, Active (IMPACT) pertussis database. Methods: IMPACT is an active surveillance network based in 12 pediatric tertiary-care hospitals across Canada. Characteristics of hospitalized cases of pertussis were compared by type of vaccine received or by birth date (if immunization records were unavailable or the child was unvaccinated). Age-stratified incidence rates were calculated by year and vaccine type. Results: Two thousand ninety-six cases of pertussis were admitted to IMPACT centers, 1174 during the whole-cell vaccine program (WCV-P) and 842 during the acellular vaccine program (ACV-P). Pertussis incidence among children Ͻ5 years old decreased significantly during the ACV-P, causing an increase in the residual proportion of cases either too young to be immunized (Ͻ2 months old: ACV-P 39% versus WCV-P 26.1%; P Ͻ 0.0001) or too young for a second dose (2-3 months old: 42.9% versus 34.2%, respectively; P Ͻ 0.0001). A significantly smaller proportion of cases (ACV-P 15.1% versus WCV-P 27.3%) occurred in infants who were old enough (4 -11 months of age) to have received 2 or 3 doses of vaccine. Conclusions: With ACV-P, pertussis hospitalizations in children 4 -59 months old decreased in frequency, consistent with improved vaccine effectiveness, but remained prominent among very young infants. Improved control strategies are needed to reduce infections among infants too young for pertussis vaccination.
I
n the prevaccine era, pertussis was a major cause of morbidity and mortality in infants and children, with an annual incidence of 159.7 per 100,000 in Canada. 1 After the introduction of the whole-cell pertussis vaccine in 1943, reported pertussis cases decreased by Ͼ90%.
1,2 However, a major resurgence of pertussis occurred throughout Canada in the early 1990s. Several studies implicated poor efficacy of the whole-cell pertussis vaccine, combined with adsorbed diphtheria-tetanus toxoids (DTwP), used from 1980 to 1998 in Canada, as the reason for the unexpected rise in cases. [3] [4] [5] [6] [7] [8] Concerns about the reactogenicity of the whole-cell vaccine led to the development of several acellular vaccines (ACV), 9 which were associated with fewer injection-site and systemic adverse events in infants and are safe for use in older children and adults. 9 -12 In addition, ACV efficacy was Ͼ85%, well above the 20%-60% efficacy estimate for the DTwP previously used in Canada. 5, 6 Because of the poor efficacy of DTwP and the safer profile and availability of ACV, between July 1997 and April 1998 all provinces and territories in Canada changed to a 5-component acellular pertussis-containing vaccine for the childhood schedule at 2, 4, 6, and 18 months and 4 to 6 years of age. This is the first population-based analysis using the Canadian Immunization Monitoring Program, Active (IMPACT) pertussis database from 1991-2004 and to examine IMPACT data for changes in the epidemiology of children hospitalized with pertussis after this nationwide program shift.
MATERIALS AND METHODS
IMPACT is an active surveillance network based in pediatric tertiary-care hospitals across Canada. IMPACT started in 5 centers in January 1991, expanded to 10 centers in April 1993, 11 in April 1995, and 12 in September 1999. The 12 IMPACT centers are located in Newfoundland, Nova Scotia, Quebec, Ontario, Manitoba, Saskatchewan, Alberta, and British Columbia and account for approximately 90% of the pediatric tertiary-care beds in the country, with referrals from all provinces and territories. About 20% of Canadian children live near an IMPACT center. 13 All centers used the same case-finding strategies, case definition and report form. Further details on the surveillance methodology have been provided elsewhere. 14 The case report form included the patient's age, sex, pre-existing medical conditions, pertussis immunization history, the diagnostic method, complications and outcome. When immunization history was unavailable or incomplete in the hospital chart, the patient's primary health care provider was contacted for additional details. Cases of pertussis in children Յ2 years of age were collected from 1991, whereas cases in children Յ16 years of age were collected starting in 1999.
The IMPACT pertussis database was examined for all cases from January 1991 through December 2004. A case of pertussis or whooping cough was either laboratory confirmed or clinically defined as a cough illness lasting for Ն2 weeks, with cough occurring in paroxysms. Post-tussive vomiting, whoop, cyanosis during coughing, or apnea was supportive evidence of a clinical case. Dual infections with Bordetella pertussis and another pathogen were reported. Compatible illnesses shown to be caused by another pathogen, nosocomial pertussis, or admissions in which pertussis was an incidental finding were not reported. Accredited clinical microbiology laboratories at each hospital conducted the laboratory testing, which included culture, serology, direct fluorescent antibody and PCR (which most frequently used the repeat insertion sequence 15 ). Characteristics of hospitalized cases of pertussis were compared by type of vaccine received or by birth date if immunization records were unavailable or the child was unvaccinated. Children born from 1991-1996 who were eligible for whole-cell pertussis vaccine programs were categorized as WCV-Program. Those born from 1999 -2004 who were eligible for acellular pertussis vaccine programs were categorized as ACV-Program. Children born in 1997-1998 were excluded from the vaccine-specific analysis because this was the transition period between the 2 vaccines. Agestratified incidence rates were calculated annually and by vaccine type. Each IMPACT center defined its local population area annually, and cases from the IMPACT center were matched to this area by the first 3 digits of the postal code. Population demographic data were obtained from local public health estimates or from national census data available from Statistics Canada. Cases from outside the locally defined catchment areas and 1 center with mostly a referral population (Toronto) were not included in the incidence calculations. Canadian routine disease notification data for all ages were used for comparison with IMPACT data in Figure 1 . All other data presented are from IMPACT. 2 and Fisher exact test were used to compare categoric variables and Student t test was used for continuous variables. Characteristics were considered significantly different between vaccines if the P value was Յ0.05; 95% exact confidence intervals for the incidence rates were calculated. SAS version 8.02 (SAS Institute, Inc, Cary, NC) was used for all analyses.
RESULTS
In total, 2,096 cases of whooping cough were admitted to IMPACT centers during the 14-year period; 80 cases occurred during the transition period (1997-1998) and were not classified as WCV-Program or ACV-Program cases. Immunization information was available for 1637 (78.1%) cases, including cases Ͻ2 months old. A total of 1338 (63.8%) cases were laboratory confirmed, 295 (22.1%) of these by multiple tests: 906 by culture, 539 by PCR, 178 by direct fluorescent antibody, and 10 by serology. About 30% of culture and PCR positives and 70% of direct fluorescent antibody and serology positives were confirmed by an additional test. A higher proportion of younger cases (0 -5 versus 6ϩ months old) were laboratory confirmed (66.3% versus 53.4%, P Ͻ 0.0001). Among the 906 whooping cough cases confirmed by culture, 5 were positive for B. parapertussis. Among the 761 (36.3%) clinically diagnosed cases, only 8% had an epidemiologic link with a laboratory-confirmed contact case; the remainder had only clinical syndromes compatible with pertussis. Significantly more ACV-Program cases were laboratory confirmed (74.2% ACV-Program versus 54.5% WCV-Program; P Ͻ 0.0001), indicating the wider recent availability of PCR (85.1% ACV-Program versus 15% WCV-Program; P Ͻ 0.0001). Subanalyses excluding PCRconfirmed cases produced similar results (data not shown) to those found in the full analysis. Continuous transmission of pertussis occurred throughout the year, with a peak during summer and fall (June-November, 63%). Seasonality of transmission did not differ by age or vaccine.
Characteristics of the hospital admissions overall and by WCV-Program and ACV-Program are summarized in Table 1 . Compared with WCV-Program, a significantly smaller number of ACV-Program cases occurred in infants who were old enough (4 -11 months of age) to have received 2-3 vaccine doses and among children 1-4-year-old. This resulted in a significant overall decrease in the proportion of 
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The Of cases with immunization records, the proportion of vaccinated infants was similar during the WCV-Program and ACV-Program. Among infants 2-3 months old, 53% and 55%, respectively, received 1 dose; in those 4 -5 months old, 43% and 45% received 1 dose, whereas 42% and 40% received 2 doses. Finally, among infants 6 -11 months old, 9% in the WCV-Program versus 15% in the ACV-Program received 1 dose, whereas 26% versus 17% had 2 and 47% versus 37%, respectively, had 3 doses. The proportions of unvaccinated infants during the WCV-Program were 47%, 15%, and 18% in the 2-to 3-, 4-to 5-, and 6-to 11-month age groups compared with 44%, 15%, and 32%, respectively, during the ACV-Program. Although the proportion of vaccinated infants did not change by program, the percentage of cases in appropriately vaccinated children 6 -23 months of age decreased significantly in the ACV-Program (ACV-Program 2.3% versus WCV-Program, 11.4%; P Ͻ 0.0001).
Of the 17 fatalities, 1 occurred in a 9-week-old infant with 1 dose of WCV 6 days before admission, whereas the remaining fatalities were unvaccinated: 12 Ͻ6 weeks of age, one 7 weeks and two 10 weeks old and one 6 months old. All fatalities were laboratory-confirmed pertussis.
We found no significant differences in ICU or hospital stay between the WCV-Program and ACV-Program cases (Table 1) . Of the complications (Table 1) , encephalitis was significantly more common among WCV-Program cases. The majority (70%) of children with encephalitis were unvaccinated infants Ͻ2 months of age. Eight of the 11 encephalitis cases were laboratory-confirmed pertussis.
In total, 1024 (48.8%) cases occurred in populationdefined geographic areas for the IMPACT centers and were included in the incidence calculations. The cases used for the population analysis had the same sex-, age-, and vaccine-type distribution as the full cohort (data not shown). The annual incidence rates (Fig. 1) illustrate the cyclic nature of pertussis in children Ͻ1 year of age, with rates peaking every 3 to 4 years, yet generally decreasing during the 14-year period, ranging from a high of 204.1 per 100,000 children in 1994 to a low of 39.3 in 2003 (Fig. 1 ). Figure 1 also shows IMPACT's annual incidence for children Ն1 year of age hospitalized with pertussis and pertussis incidence in all ages in Canada from notifiable disease reports. IMPACT data showed incidence was significantly lower with ACV in children Ͻ5 years of age. Incidence rates in the WCV-Program versus ACV-Program were 136.1 (95% CI, 124.2-148.8) versus 85.7 (95% CI, 77.7-94.4), respectively, in children Ͻ1 year and 4.6 (95% CI, 3.5-5.9) versus 0.7 (95% CI, 0.4 -1.1) in children 1-4 years. Follow-up time was limited in the 5-to 9-year age group, but incidence rates in the WCVProgram versus the ACV-Program were 0.2 (95% CI, 0.1-0.6) and 0.1 (95% CI, 0.0 -0.3), respectively. Incidence in 10-to 16-year-olds in the WCV program was 0.6 (95% CI, 0.3-1.0); follow-up time was insufficient to determine ACV-Program rates.
DISCUSSION
The change from WCV to ACV in Canadian immunization programs has been associated with a rapid decline in the overall incidence of pertussis and in hospitalized pertussis. The decrease in incidence among children Ͻ5 years old is consistent with improved effectiveness of the ACV. However, ACV appears to have little influence on cases Ͻ3 months old, which still account for a high proportion of pertussis-related hospital admissions. Despite improved vaccine effectiveness, transmission to susceptible infants continues because of ongoing transmission in incompletely immunized children, those left vulnerable despite vaccination, and adolescents and adults without immunity. 
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We believe the decrease in hospitalizations during the 14-year period and in children Ͻ5 years of age during the ACV program to be related to improved vaccine effectiveness of the ACV compared with the WCV, resulting in a decrease in disease incidence and greater herd immunity. The observed decline in hospitalization incidence rates in children Ͻ5 years of age mirrors national data for children Ͻ5 years old, 16 -18 vaccine coverage rates remain stable, 19 and IMPACT surveillance activities have not decreased. In fact, the number of centers involved with surveillance increased and the number of laboratory-confirmed cases increased, indicating more complete surveillance.
The reduction shown in encephalitis cases may reflect the decrease in overall rates of pertussis hospitalizations rather than direct effects of ACV. The majority of encephalitis complications occurred in infants too young for immunization during both vaccine periods.
Except for immunization history, our data were limited to information reported in the hospital chart. Additionally, infection rates were calculated from population estimates from several sources, each with an associated margin of error; therefore, the calculations provide only a crude estimate of the incidence. Furthermore, IMPACT captures only hospitalized cases from the IMPACT center, so the rates underestimate the true incidence of pertussis. Our analysis is also limited by its short look at a cyclic disease. Consequently, it is possible but unlikely that the decline in incidence simply reflects the natural variation of this disease. Finally, our study period was not long enough to evaluate the effects of the ACV in children Ͼ7 years of age.
In spite of these limitations, our data are unique for their national scope, representativeness of tertiary pediatric populations, duration, extensive case finding, and linkage of clinical, microbiologic and population data. Since 1999, IMPACT has provided consistent, standardized reporting for pediatric hospitalized pertussis in all age groups, not just infants. It allows examination of the differences between 2 vaccines over time and evaluation of the epidemiology of children hospitalized with pertussis.
Despite an overall decrease in the incidence of hospitalized pertussis, the highest incidence remains in children Ͻ1 year old. Further, the highest proportion of cases occurs in children too young to be immunized. The first dose of vaccine given at 6 weeks of age, instead of the current 8 weeks, may reduce disease. 20 However, the majority of deaths occurred in infants less than 6 weeks of age, a group that would remain unaffected by earlier immunization. Because the transmission source for young infants may depend on the level of vaccination coverage in the population, 21 countries with higher coverage, such as Canada, should target booster immunizations at adolescents and adults. 22, 23 Kandola et al 24 showed booster doses in adolescents and adults living in Canada's Northwest Territories dramatically reduced cases in infants younger than 2 months. Finally, maternal ACV immunization may provide protection during the neonatal period without interfering with the infant immune response to the first dose of vaccine at 2 months of age. 25, 26 In contrast to the United States, where there has been an increase in pertussis incidence and hospitalization among young infants since 1990, 27, 28 our study shows that in Canada, the change from the WCV to the ACV was followed by a lower incidence of pediatric hospitalizations for pertussis. This comes as no surprise, given the lower effectiveness of the WCV used in Canada when compared with that used in the United States. Recent data from the United States confirms that ACVs are highly effective. 29 The challenge now is to develop effective strategies to protect infants too young to be immunized. The recent NACI recommendation for 1 dose of acellular pertussis vaccine during adolescence or adulthood may help achieve this objective. 
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